TST901

TST901 is a first-in-class bispecific antibody targeting both sclerostin and another undisclosed target and with prolonged half-life. TST901 is designed for the treatment of patients with severe osteoporosis at risk of fracture with less frequent dosing and multiple mechanism of actions.It is at preclinical stage.